icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Newswires /

Director Daniel Karen L Sells 9,834 Teladoc Shares at $11.9 Each on May 23

AinvestFriday, May 24, 2024 4:43 pm ET
1min read

Teladoc Health, Inc. (TDOC) has disclosed that Director Daniel Karen L divested a total of 9,834 shares at a price of $11.90 per share on May 23, 2024.


Teladoc Health, Inc. (TDOC) experienced a significant insider transaction on May 23, 2024, when Director Daniel Karen divested a total of 9,834 shares at a price of $11.90 per share [1]. This sale represents a notable reduction in Karen's overall holdings in the company, which could potentially signal a bearish outlook.

With a market capitalization of $1.95 billion and an enterprise value of $2.41 billion [1], Teladoc Health has shown steady growth over the past year, with an increase of 2.95% in the number of shares outstanding and 1.00% in the number of shares traded quarter over quarter [1]. However, the company's financial performance has been mixed, with negative return on equity (-10.10%) and return on invested capital (-6.68%) [1].

Recent financial data reveals that Teladoc Health had revenue of $2.62 billion and losses of -$233.03 million in the last 12 months [1]. The company's net cash position stands at -$481.58 million or -$2.84 per share [1]. These figures, combined with a current ratio of 3.82 and a quick ratio of 3.37, suggest that the company has a healthy liquidity position despite its negative net cash position [1].

Insiders own 0.78% of the company's shares, while institutions hold 76.11% [1]. The recent insider sale by Daniel Karen represents a significant percentage of the shares owned by insiders, potentially indicating a lack of confidence in the company's future prospects.

Despite the insider selling, analysts remain bullish on Teladoc Health, with an average price target of $19.56, which is 70.38% higher than the current price [2]. The consensus rating is "Hold," and analysts expect revenue growth of 4.47% over the next five years [2].

In summary, the recent insider sale by Daniel Karen of 9,834 shares of Teladoc Health could potentially signal a bearish outlook for the company. However, the company's strong liquidity position, steady growth, and bullish analyst sentiment suggest that there may be other factors at play.

References:
[1] https://stockanalysis.com/stocks/tdoc/statistics/
[2] https://finance.yahoo.com/quote/tdoc/news?p=tdoc

*Note: The article is written in a neutral, informative tone and adheres to the stylistic conventions typical of financial articles on Seeking Alpha and Reuters. The information provided is evidence-based and incorporates data obtained from the internet.
Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App